Savara (SVRA) is rated a speculative BUY at $4.72 with a $7 twelve-month price target, anticipating a crucial FDA decision on November 22 regarding its drug molgramostim. The company shows strong clinical efficacy data in Phase 3 trials, but faces significant risks related to manufacturing and regulatory approval. With $129.6 million in cash, its financial runway is limited, and future profitability depends on successful approval, manufacturing reliability, and market adoption. The FDA decision could unlock further funding, but royalties and milestone payments may impact long-term profits.
Savara's FDA risk is the subject, with Pluang's Health sector data providing context. As of Nov 15, 2026 00:41 WIB, out of 150 priced Health-sector US stocks on Pluang, 71 rose and 77 fell. Among notable movers, IONS rose 6.41% to USD 29.06 with 100% buy orders and a typical hold time of 4 days, contrasting with HRTX and SMMT, which both fell 6.14% to USD 0.31 and USD 14.15 respectively, with HRTX showing a longer hold time of 39 days and a majority sell order activity of 56%.
XRP dropped to $0.96, falling out of the top 5 cryptocurrencies by market value, now ranking sixth behind USDC. The coin has lost 26% since November 5, driven by a broader crypto market sell-off and no new inflows into US XRP ETFs since late October....
Bitcoin dropped below its 200-week moving average to around $65,700, marking the lowest level since August 2026. This decline was driven by over $1.2 billion in liquidations, mostly from long positions, and a seventh consecutive day of outflows from ...
Cardano's ADA price fell about 8.8% to $0.158 on November 14, 2026, marking its lowest level since late July. The drop coincided with founder Charles Hoskinson's livestream stating the original Cardano roadmap is complete, though he remains involved ...
Super Micro Computer reported strong Q1 FY27 results, surpassing revenue and earnings expectations, driven by AI solutions now making up 71% of sales. OEM and data center revenues saw significant growth, although gross margins declined due to product...
Hyperliquid (HYPE) experienced a sharp price decline of 2.81% within one hour, falling to $65.47, and a total 24-hour drop of 9.87%. This price movement was accompanied by significant long position liquidations totaling $2.66 million across Binance, ...
